Vivos Therapeutics reports increase in product revenue and decrease in operating expenses for Q1 2025

From GlobeNewswire: 2025-05-15 16:20:00

Vivos Therapeutics, Inc. reported an 8% increase in product revenue and a 5% decrease in operating expenses for the first quarter of 2025. The company is focused on its new marketing and distribution model, with a pending acquisition of The Sleep Center of Nevada. Vivos’ net loss increased by 3% to $3.9 million, with revenue from product sales up 8% year over year. The acquisition of SCN is expected to close within two months, positioning Vivos for growth. Vivos encourages investors to join their conference call today at 5:00 p.m. Eastern time to learn more about their strategic collaborations and future growth plans.

Vivos, a medical technology company, specializes in treatments for sleep-related breathing disorders like obstructive sleep apnea. They aim to address the root causes of these disorders with innovative technology and partnerships with healthcare providers. The company’s groundbreaking CARE devices are FDA-cleared for treating OSA in adults and children. Vivos is focused on empowering healthcare providers to offer effective, noninvasive solutions for patients. They are dedicated to improving breathing and sleep health for those suffering from these conditions.



Read more at GlobeNewswire: Vivos Therapeutics Reports First Quarter 2025 Financial